Orthocell has announced that it has received a Research and Development (R&D) Tax Incentive refund of A$3,051,483 for the financial year 2022/2023.
Quarterly Report – Period To 31 March 2024
Orthocell has today published its Quarterly Report for the period ended 31 March 2024.
Proactive Interview with Paul Anderson
Orthocell Managing Director, Paul Anderson, spoke with Jonathan Jackson at Proactive to provide an update on the Company’s market authorisation study for nerve repair device, Remplir™.
Orthocell Successfully Completes Surgeries for Remplir™ US Market Authorisation
Orthocell has announced that it has successfully completed the first stage of the Remplir™ US 510(k) market authorisation nerve repair study.
Proactive | Interview with CEO Paul Anderson
Orthocell CEO Paul Anderson spoke with Jonathan Jackson at Proactive about the Company’s recent strategic placement of $3.5 million, adding prominent investors to the share register.
The West Australian | Chris Ellison, Rod Jones and the McCuskers jump into Orthocell
Orthocell’s Company-led strategic placement has been reported in The West Australian newspaper today, in an article by Senior Business Report Sean Smith titled “Chris Ellison, Rod Jones and the McCuskers jump into Orthocell”.
Orthocell Completes $3.5M Strategic Placement
Orthocell has today announced that it has completed a Company-led Strategic Placement to raise $3.5 million.
Orthocell submits Singapore Regulatory Application for Remplir™
Orthocell has today announced that the Company has submitted a regulatory application to the Health Services Authority of Singapore for approval to market and sell Remplir™ for use in peripheral nerve repair procedures.
The Hon Kim Beazley AC Joins Orthocell Board
Orthocell has appointed Australia’s former US ambassador and Governor of Western Australia, The Hon Kim Beazley AC, as an Independent Non-Executive Director to the Board.
ABC News | Tennis elbow treatment trial successes offer hope for sufferers wary of surgery
Orthocell recently released compelling new data from our clinical trial comparing the effectiveness of our tendon cell therapy (OrthoATI™) to surgery, in the treatment of severe, chronic lateral epicondylitis – also known as tennis elbow.
This week, Orthocell was featured in a national news story (television, radio, online) by ABC News reporter, Erin Somerville, who shared the story of Annette Skirka – a patient whose debilitating experience with tennis elbow prevented her from pursuing her passion for mountaineering. This led her to explore a number of treatment options, before eventually participating in our clinical trial.
Click here to read Annette’s story.
Click here to watch the ABC News segment